特应性皮炎治疗的新视野：JAK抑制剂。
A New Horizon for Atopic Dermatitis Treatments: JAK Inhibitors.
作者信息
Tampa Mircea, Mitran Cristina Iulia, Mitran Madalina Irina, Georgescu Simona Roxana
机构信息
Department of Dermatology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Department of Dermatology, "Victor Babes" Clinical Hospital for Infectious Diseases, 030303 Bucharest, Romania.
出版信息
J Pers Med. 2023 Feb 22;13(3):384. doi: 10.3390/jpm13030384.
Abstract
The article entitled "Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials" that belongs to the Special Issue, " Personalized medicine in the field of inflammatory skin diseases", a collection of articles addressing the current critical issues in the pathogenesis and management of chronic inflammatory skin disorders, represents a valuable work that has contributed to elucidating the role of Janus kinase (JAK) inhibitors as a treatment option for atopic dermatitis (AD), as well as their safety profiles [...].
摘要
题为《JAK抑制剂在特应性皮炎中的应用：临床试验的最新系统评价和荟萃分析》的文章属于特刊“炎症性皮肤病领域的个性化医学”，该特刊收集了一系列探讨慢性炎症性皮肤病发病机制和管理中当前关键问题的文章，是一项有价值的工作，有助于阐明JAK抑制剂作为特应性皮炎（AD）治疗选择的作用及其安全性概况[...]。
相似文献
1
A New Horizon for Atopic Dermatitis Treatments: JAK Inhibitors.特应性皮炎治疗的新视野：JAK抑制剂。
J Pers Med. 2023 Feb 22;13(3):384. doi: 10.3390/jpm13030384.
2
Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials.Janus激酶抑制剂在特应性皮炎中的应用：临床试验的最新系统评价和荟萃分析
J Pers Med. 2021 Apr 7;11(4):279. doi: 10.3390/jpm11040279.
3
Abrocitinib in atopic dermatitis: review of the current literature and clinical trials.阿泊替尼治疗特应性皮炎：当前文献和临床试验综述。
Drugs Today (Barc). 2022 Aug;58(8):373-387. doi: 10.1358/dot.2022.58.8.3408817.
4
Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications.在特应性皮炎应用中，全身性 Janus 激酶抑制剂的安全性考虑。
J Dermatol. 2021 Nov;48(11):1631-1639. doi: 10.1111/1346-8138.16116. Epub 2021 Aug 30.
5
Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.外用 Janus 激酶和磷酸二酯酶 4 抑制剂治疗特应性皮炎的疗效和安全性：一项网状荟萃分析。
J Dermatol. 2021 Dec;48(12):1877-1883. doi: 10.1111/1346-8138.16126. Epub 2021 Sep 6.
6
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.Janus 激酶抑制剂治疗特应性皮炎的药效学。
Expert Opin Drug Metab Toxicol. 2022 May;18(5):347-355. doi: 10.1080/17425255.2022.2099835. Epub 2022 Jul 12.
7
The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis.Janus激酶抑制剂治疗特应性皮炎的有效性：一项系统评价和荟萃分析。
Dermatol Ther. 2020 Jul;33(4):e13685. doi: 10.1111/dth.13685. Epub 2020 Jul 14.
8
The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.Janus 激酶抑制剂在特应性皮炎患者中的疗效：系统评价和网络荟萃分析。
Dermatol Ther. 2021 Sep;34(5):e15098. doi: 10.1111/dth.15098. Epub 2021 Aug 25.
9
The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.特应性皮炎系统使用 JAK 抑制剂的安全性：系统评价和网络荟萃分析。
Eur J Clin Pharmacol. 2022 Dec;78(12):1923-1933. doi: 10.1007/s00228-022-03400-4. Epub 2022 Oct 7.
10
The suitability of treating atopic dermatitis with Janus kinase inhibitors.用 JAK 抑制剂治疗特应性皮炎的适宜性。
Expert Rev Clin Immunol. 2022 May;18(5):439-459. doi: 10.1080/1744666X.2022.2060822. Epub 2022 May 4.
引用本文的文献
1
Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.评估斑秃的现有和新型JAK抑制剂：一项叙述性综述
Dermatol Ther (Heidelb). 2025 Aug 12. doi: 10.1007/s13555-025-01517-9.
2
Nakai Extract Attenuates Atopic Dermatitis-like Symptoms by Regulating Skin Barrier Factors and Inhibiting the JAK/STAT Pathway.中井提取物通过调节皮肤屏障因子和抑制JAK/STAT信号通路减轻特应性皮炎样症状。
Int J Mol Sci. 2025 Mar 25;26(7):2994. doi: 10.3390/ijms26072994.
3
Baricitinib in the Treatment of Severe Atopic Dermatitis Resistant to Cyclosporine: A Case Report Involving Two Cases.巴瑞替尼治疗对环孢素耐药的重度特应性皮炎：两例病例报告
Cureus. 2025 Feb 25;17(2):e79638. doi: 10.7759/cureus.79638. eCollection 2025 Feb.
4
JAK inhibition decreases the autoimmune burden in Down syndrome.JAK抑制可减轻唐氏综合征中的自身免疫负担。
Elife. 2024 Dec 31;13:RP99323. doi: 10.7554/eLife.99323.
5
JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician.皮肤科中的JAK 1-3抑制剂和TYK-2抑制剂：初级保健医生的实用要点
J Family Med Prim Care. 2024 Oct;13(10):4128-4134. doi: 10.4103/jfmpc.jfmpc_112_24. Epub 2024 Oct 18.
6
Pharmacological Trends in the Management of Atopic Dermatitis: A Comprehensive Review.特应性皮炎管理中的药理学趋势：全面综述
Cureus. 2024 Jul 11;16(7):e64302. doi: 10.7759/cureus.64302. eCollection 2024 Jul.
7
Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review.乌帕替尼治疗中重度特应性皮炎的疗效和安全性：系统评价。
PLoS One. 2024 Jul 26;19(7):e0306463. doi: 10.1371/journal.pone.0306463. eCollection 2024.
8
JAK inhibition decreases the autoimmune burden in Down syndrome.JAK抑制可减轻唐氏综合征中的自身免疫负担。
medRxiv. 2024 Oct 16:2024.06.13.24308783. doi: 10.1101/2024.06.13.24308783.
9
Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain.阿巴西普与西班牙其他用于重度特应性皮炎的全身治疗药物的成本效益分析。
Pharmacoecon Open. 2024 Mar;8(2):291-302. doi: 10.1007/s41669-023-00459-2. Epub 2024 Jan 18.
本文引用的文献
1
Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta-analysis.口服 Janus 激酶抑制剂治疗特应性皮炎：一项系统评价和荟萃分析。
Skin Health Dis. 2022 May 23;3(1):e133. doi: 10.1002/ski2.133. eCollection 2023 Feb.
2
Oral Janus kinase inhibitors for atopic dermatitis.用于特应性皮炎的口服 Janus 激酶抑制剂。
Ann Allergy Asthma Immunol. 2023 May;130(5):577-592. doi: 10.1016/j.anai.2023.01.020. Epub 2023 Feb 1.
3
Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review.局部JAK抑制剂治疗儿童和成人特应性皮炎的疗效和安全性：一项系统评价。
Exp Dermatol. 2023 May;32(5):599-610. doi: 10.1111/exd.14753. Epub 2023 Feb 3.
4
FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology.美国食品药品监督管理局批准芦可替尼（Opzelura）用于白癜风治疗：皮肤科领域的一项突破。
Ann Med Surg (Lond). 2022 Aug 28;81:104499. doi: 10.1016/j.amsu.2022.104499. eCollection 2022 Sep.
5
What's New in Topicals for Atopic Dermatitis?特应性皮炎的局部治疗有哪些新进展？
Am J Clin Dermatol. 2022 Sep;23(5):595-603. doi: 10.1007/s40257-022-00712-0. Epub 2022 Sep 1.
6
Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis.特应性皮炎与静脉血栓栓塞事件风险及 Janus 激酶抑制剂治疗的关联：一项系统评价和荟萃分析
JAMA Dermatol. 2022 Nov 1;158(11):1254-1261. doi: 10.1001/jamadermatol.2022.3516.
7
The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review.JAK/STAT信号通路及其在特应性皮炎治疗中的选择性抑制：一项系统评价
J Clin Med. 2022 Jul 29;11(15):4431. doi: 10.3390/jcm11154431.
8
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.特罗利单抗治疗中重度特应性皮炎成人患者的 2 年长期安全性和疗效：ECZTEND 开放标签扩展试验的中期分析。
J Am Acad Dermatol. 2022 Oct;87(4):815-824. doi: 10.1016/j.jaad.2022.07.019. Epub 2022 Jul 19.
9
First Systemic Treatment for Severe Alopecia Is Approved.首个用于严重脱发的全身治疗方法获批。
JAMA. 2022 Jul 19;328(3):235. doi: 10.1001/jama.2022.11869.
10
Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis.比较中重度特应性皮炎中单克隆抗体与 Janus 激酶抑制剂的疗效和安全性：系统评价和荟萃分析。
Acta Derm Venereol. 2022 Aug 24;102:adv00764. doi: 10.2340/actadv.v102.2075.
Zotero 插件